These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
443 related articles for article (PubMed ID: 28801347)
1. A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up. Rajeswarie RT; Rao S; Nandeesh BN; Yasha TC; Santosh V J Clin Pathol; 2018 Apr; 71(4):323-329. PubMed ID: 28801347 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting. Jain S; Gupta P; Shankar KB; Singh R; Siraj F J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575 [TBL] [Abstract][Full Text] [Related]
4. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834 [TBL] [Abstract][Full Text] [Related]
13. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590 [TBL] [Abstract][Full Text] [Related]
14. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance. Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574 [TBL] [Abstract][Full Text] [Related]
15. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas. Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432 [TBL] [Abstract][Full Text] [Related]
16. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas. Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929 [TBL] [Abstract][Full Text] [Related]
17. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Ikemura M; Shibahara J; Mukasa A; Takayanagi S; Aihara K; Saito N; Aburatani H; Fukayama M Histopathology; 2016 Aug; 69(2):260-7. PubMed ID: 26741321 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683 [TBL] [Abstract][Full Text] [Related]
19. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. Malzkorn B; Reifenberger G Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086 [TBL] [Abstract][Full Text] [Related]
20. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas. Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]